• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 522319 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414745609 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414745609 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Watch for Continued Losses in Shares of Aastrom Biosciences (ASTM)

Published on Mon, 06/24/2013 - 14:23
By Peter Chu

Shares of Aastrom Biosciences (NASDAQ:ASTM) traded at a new 52-week low today of $0.45. Approximately 59,000 shares have changed hands today, as compared to an average 30-day volume of 171,000 shares.

Potential upside of 155.3% exists for Aastrom Biosciences, based on a current level of $0.48 and analysts' average consensus price target of $1.23. The stock should run into initial resistance at its 50-day moving average (MA) of $0.59 and subsequent resistance at its 200-day MA of $1.16.

In the past 52 weeks, shares of Aastrom Biosciences have traded between the current low of $0.45 and a high of $2.20 and are now at $0.48. In the last five trading sessions, the 50-day moving average (MA) has fallen 3.7% while the 200-day MA has slid 2.4%.

Aastrom Biosciences, Inc. develops autologous stem/progenitor cell products for the repair/regeneration of tissues based on Tissue Repair Cell (TRC) adult stem cell technology. The Company's products contain bone marrow stem and progenitor cells that are produced from cells originating from the patient.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Take-Two Interactive Software Looks to C...

Shares of Take-Two Interactive Software (NASDAQ:TTWO) traded at a new 52-week high toda ...

Shares of Talisman Energy Fall Below Pre...

Shares of Talisman Energy (NYSE:TLM) traded at a new 52-week low today of $6.12. Appro ...

Recent 52-Week High Exceeded in Shares o...

Shares of Hanover Insurance (NYSE:THG) traded at a new 52-week high today of $66.88. T ...

Recent 52-Week Low Surpassed in Shares o...

Shares of Taseko Mines (AMEX:TGB) traded at a new 52-week low today of $1.35. This new ...

Transglobe Energy Looks to Continue to T...

Shares of Transglobe Energy (NASDAQ:TGA) traded today at $4.35, breaking its 52-week lo ...

Shares of TFS Financial Rise Above Previ...

Shares of TFS Financial (NASDAQ:TFSL) traded today at $15.09, breaking its 52-week high ...

Watch for Continued Gains in Shares of T...

Teva Pharmaceutical Industries (NASDAQ:TEVA) traded at a new 52-week high today of $55. ...

Shares of Integrys Energy Rise to a New ...

Integrys Energy (NYSE:TEG) traded at a new 52-week high today of $72.23. So far today ...